INTRODUCTION
Atrial fibrillation is the most common arrhythmia encountered in clinical practice, affecting an estimated 2.7 million individuals in the United States and 5.6 million by 2050 [1] . Among Medicare beneficiaries aged 67 or older, the prevalence of atrial fibrillation has sharply increased from 6.7% in 1998 to 8.6% in 2007 [2 & ]. Among these patients, one in four will die within one year after diagnosis. The most dreaded consequence of atrial fibrillation is stroke, which is associated with 15% of the 700 000 ischemic strokes per year. The proportion of strokes attributable to atrial fibrillation increases steeply from 1.5% at 50-59 years of age to 23.5% at 80-89 years of age [3, 4] .
Oral anticoagulation has been shown to substantially reduce the risk of ischemic stroke by up to 60% [5] , but at the expense of an increase in risk of bleeding, including major intestinal bleeding and intracranial hemorrhage, which may be disabling or fatal. Among patients at low risk for major bleeding, the benefits of anticoagulation generally outweigh the risks, and oral anticoagulation is recommended for patients with atrial fibrillation and one or two accompanying risk factors for stroke [6] [7] [8] .
Kidney function is strongly associated with the risk of atrial fibrillation [9, 10 anticoagulation strategies. Therefore, there is uncertainty and controversy regarding the risks and benefits of anticoagulation in patients with atrial fibrillation on hemodialysis. The objective of this review is to dissect the available evidence on the burden of atrial fibrillation in the hemodialysis population, weigh the considerations for and against the use of oral anticoagulation, and also examine the sparse evidence on the effectiveness and safety of this treatment strategy in patients undergoing hemodialysis. [13] . Interestingly, an international comparison showed considerable heterogeneity, with prevalence estimates ranging from 5.6% (Japan) to 24.7% (Belgium) [13] . Many patients appear to have atrial fibrillation even prior to starting dialysis. In patients initiating dialysis in 2003 or 2004 at a large national dialysis provider in the United States, 4.5% had been diagnosed and documented with atrial fibrillation by the time of their first treatment [14] . In older patients (67 years) initiating dialysis in the United States between 1995 and 2008, 34% had been diagnosed with atrial fibrillation in the two years preceding their dialysis initiation [15] . Older age and white race as well as several cardiovascular and other comorbidities were associated with increased risk of atrial fibrillation. From the studies that specifically investigated trends over time, it is also apparent that both the incidence and the prevalence of atrial fibrillation in US hemodialysis patients have been increasing [11 && ,15].
BURDEN OF ATRIAL FIBRILLATION IN THE HEMODIALYSIS POPULATION

UTILIZATION PATTERNS OF ORAL ANTICOAGULATION IN HEMODIALYSIS PATIENTS WITH ATRIAL FIBRILLATION
In general, warfarin use has been found to be rather low in hemodialysis patients with atrial fibrillation. In a study of older hemodialysis patients with atrial fibrillation in two eastern states, only one quarter had filled a prescription of warfarin in the previous 45 days [16] . In the DOPPS, 26% of prevalent US hemodialysis patients with atrial fibrillation were reported to be taking warfarin [13] . Neither of these studies was able to determine the specific indication for warfarin use (atrial fibrillation or other, e.g., vascular access patency) or the level of anticoagulation achieved. Of 1671 patients who had preexisting atrial fibrillation and initiated hemodialysis with a large national dialysis provider in 2003/2004, 45% were reported to have received warfarin at dialysis initiation [14] . International normalized ratios (INRs) were unavailable in 204/747 patients; of the remainder, 10% had an INR less than 1.5, 29% an INR between 1.5 and 1.9, 60% between 2 and 3 (the recommended target range) [8] , and 11% were above target range with an INR more than 3 at the time of dialysis initiation.
The slightly higher rate of warfarin use in the latter study can be partly explained by selection factors (eligible patients had to survive and remain on hemodialysis for 3 months after initiation) and the fact that only incident patients were studied. It is possible that warfarin is discontinued in a significant number of patients initiating hemodialysis who had used it prior to starting maintenance hemodialysis. These data indicate that the utilization of anticoagulation in hemodialysis patients is much lower than has been shown in the general population [17] [18] [19] [20] .
KEY POINTS
Atrial fibrillation is common in patients undergoing chronic hemodialysis, but few of these patients receive oral anticoagulation with warfarin.
No randomized trials have studied the efficacy and safety of oral anticoagulation in hemodialysis patients with atrial fibrillation.
Few observational studies have studied this clinical question and none have found net benefits from oral anticoagulation using warfarin.
Large efficacy trials of several newer anticoagulants did not include any dialysis patients.
No general recommendations in favor of oral anticoagulation in hemodialysis patients with atrial fibrillation can be made at this point.
The rather low use of warfarin in hemodialysis patients with atrial fibrillation in the studies discussed in the previous section appears to reflect skepticism about the net benefits of warfarin anticoagulation. Indeed, the studies that established the efficacy of warfarin did not include patients with advanced kidney disease and it is possible that the evidence from populations without hemodialysis cannot be extrapolated to patients who are dependent on it. There are several reasons that the relation between risks and benefits may be shifted toward reduced net benefit or even harm in patients undergoing dialysis.
RISK OF STROKE
On the one hand, the risk of thromboembolic events in the dialysis population is high [21, 22] , which could possibly enhance benefits from oral anticoagulation. Compared to the general population, dialysis patients have four to 10 times the risk of being hospitalized with an ischemic stroke, dependent on their race and sex (white men: adjusted rate ratio, aRR ¼ 6.1; white women: aRR ¼ 10.1; African American men: aRR ¼ 4.3; African American women: aRR ¼ 6.5) [21, 23] . Compared to the rate in the general population, dialysis patients over age 65 had more than 400 excess ischemic stroke events per 10 000 person-years in men and more than 600 in women [21] . Focusing solely on the US dialysis population, the crude rate of ischemic stroke was 33 per 1000 person-years [22] . However, due to the high burden of atherosclerotic disease, hemodialysis patients may present with atherothrombotic stroke (rather than embolic stroke), which could also explain the reduced treatment benefit with warfarin.
RISK OF BLEEDING
On the other hand, dialysis patients are also at a high risk of bleeding events, making oral anticoagulation potentially more risky. The age-adjusted rate ratios of hospitalization for hemorrhagic stroke in dialysis patients compared to the general population were 5.9 for white men, 6.7 for white women, 4.1 for African American men, and 4.0 for African American women [21] . Dialysis patients are also at particular risk of another type of bleeding event: upper gastrointestinal bleeding [24] . In a recent study of US dialysis patients whose primary insurance was Medicare fee-for-service, the rate of nonvariceal upper gastrointestinal bleeding was estimated to be 57 episodes per 1000 person-years using a stringent definition or 328 episodes per 1000 person-years using a more lenient definition [25] . These rates were up to two orders of magnitude higher than those reported in the general population, and 30-day mortality following such an event was high, exceeding 10% [25] . In addition to hemorrhagic stroke and upper gastrointestinal bleed, hemodialysis patients are also at risk of minor bleeding, specifically from their vascular access puncture sites [26] . These high bleeding risks may also be augmented by the relatively widespread use of other medications affecting coagulation and thrombostasis other than warfarin, including aspirin, clopidogrel, and heparin in this population [14, 27, 28] .
Finally, there has been concern and controversy about warfarin-associated risk of accelerated vascular calcification in patients undergoing maintenance hemodialysis [29, 30] . Although the argument is mostly built on theoretical grounds and in-vitro findings, there are clinical data weakly linking warfarin use and its duration to aortic valve calcification in dialysis patients [31] . In addition, warfarin use has long been identified as a risk factor for calcific uremic arteriolopathy ('calciphylaxis') [32] , although it is clearly a component cause and not sufficient cause for the development of this often life-threatening condition.
DIRECT EVIDENCE ON THE EFFECTIVENESS AND SAFETY OF WARFARIN ANTICOAGULATION IN PATIENTS UNDERGOING HEMODIALYSIS
To date, no randomized trials have tested the efficacy of warfarin anticoagulation in patients undergoing dialysis and studies in the general or other specific populations (e.g., heart failure) have systematically excluded patients with end-stage renal disease (ESRD). Only a few studies have examined the outcomes associated with warfarin anticoagulation in dialysis patients [13,14,33-36,37 && ]. Herein we examine the three most recent and largest studies ( Table 1) .
Chan et al. [14] used the clinical database of a large US dialysis provider and identified from all patients initiating hemodialysis in 2003 and 2004 those who had a diagnosis of atrial fibrillation documented in the electronic medical record at the time of their first outpatient dialysis. To be included in the study, patients had to have begun dialysis within 30 days and were required to survive 90 days. Warfarin use within 90 days of initiation of hemodialysis was ascertained from medical records. The identified 1671 patients were then followed for the event of stroke (any; ischemic; hemorrhagic), also derived from electronic medical records, or death.
In multivariable adjusted as well as in propensity score-matched analyses, the risk of any stroke was double in patients with baseline warfarin use compared to those who had no warfarin use recorded. When examining ischemic and hemorrhagic stroke events separately, both were found to be associated with baseline warfarin use: users had 1.81 times the rates of ischemic stroke and 2.22 times the rates of hemorrhagic stroke (Table 1) .
Wizemann et al. [13] used data from the DOPPS and identified patients who had been reported to have had atrial fibrillation at enrollment into DOPPS. Presumably, warfarin use was also queried at the same time. All 3245 patients with atrial fibrillation at baseline were then followed for the event of stroke (hospitalized or listed as cause of death) and associations with baseline warfarin use were then estimated. Age appeared to have modified the association, with warfarin users over age 75 years experiencing 2.17 times higher stroke rates than otherwise similar patients who were not reported to have used warfarin at baseline. The associations were not significant, though also in the direction of harm, in the two younger age strata. Specific type of stroke (ischemic versus hemorrhagic) was not ascertained in this study.
Winkelmayer et al. [37 && ] used insurance data from Medicare and several state-sponsored prescription drug benefit programs for the elderly in Pennsylvania and New Jersey. They assembled a cohort of older patients who initiated dialysis without any evidence of diagnosed atrial fibrillation in insurance claims preceding ESRD incidence. These patients were then followed for a first hospitalization in which atrial fibrillation was diagnosed and coded in billings submitted to Medicare. Patients were then required to not have received warfarin prior to this hospitalization and had to survive 30 days after discharge. During this 30-day window, initiation of warfarin treatment was ascertained from filled prescriptions for this drug. Patients were then followed for the appearance of healthcare claims containing diagnosis codes for ischemic or hemorrhagic stroke. In a propensity-matched cohort of warfarin users and nonusers, initiators of warfarin after their first hospitalization when atrial fibrillation was recorded had 2.38 times the risk of hemorrhagic stroke compared with otherwise similar patients who did not initiate warfarin within 30 days of discharge. The association between warfarin use and the risk of ischemic stroke, however, was null, though with confidence limits that included the potential for sizeable benefit (a 39% risk reduction) and harm (a 37% risk increase).
Mortality from any cause was not associated with warfarin use in the two studies that reported this association [14,37 && ]. None of the three studies found any associations between warfarin use and gastrointestinal bleeding [37 && ] and hospitalizations for bleeding [13, 14] .
One potential explanation for increased bleeding events on warfarin may be the quality of anticoagulation or INR control in hemodialysis patients. Time in therapeutic range (TTR; INR between 2.0 and 3.0) has been repeatedly demonstrated to be a potent predictor of warfarin effectiveness and safety [38] . However, comorbidities are associated with decreased TTR in randomized trials and observational studies [39] . Chronic kidney disease decreases TTR [40] and patients on hemodialysis have the most significant declines in risk-adjusted TTR [41] .
For the clinician, it is challenging to make sense of these disparate findings and to synthesize a recommendation from these studies [42] . Although the finding that warfarin use (and anticoagulation intensity [14] ) associates with increased risks of hemorrhagic stroke is plausible, it is the difference in the reported associations with ischemic (and any) stroke that baffle the consumer of this research. Clearly, the three studies differ quite a bit in their setting, the way data are collected, and in their study design and analytical approach. It is possible that studies that focus on patients with preexisting atrial fibrillation and existing users of warfarin induce biases by not focusing on the moment of decision-making, the time when atrial fibrillation was first diagnosed, and the time when the decision whether to prescribe warfarin or not was made. A detailed discussion on inception cohorts and new user designs is available elsewhere [37 && ] and does not need to be repeated here. But all studies have in common that treatment was assigned based on clinical information and not by the flip of a coin as would occur in a clinical trial. Therefore, the evidence from all these studies needs to be consumed with caution.
POTENTIAL OF EMERGING ANTICOAGULANTS IN PATIENTS ON HEMODIALYSIS
Because the excess bleeding risk in dialysis patients may be, at least in part, due to poor INR control with warfarin, anticoagulants without this variability in potency could be effective. Over the last several years, one oral direct thrombin inhibitor (dabigatran) and two oral factor Xa inhibitors (rivaroxaban and apixaban) have been studied against warfarin in three large pivotal phase III randomized trials [43] [44] [45] . Unfortunately, patients with severe chronic kidney disease (estimated glomerular filtration rate <25 or 30 ml/min/1.73 m 2 ) were excluded from all three trials. Still, the US Food and Drug Administration (FDA) approved half-dose (75 mg twice daily) dabigatran in patients with creatinine clearance of 15-30 ml/min, even in the absence of randomized trial data. Unfortunately, postmarketing surveillance reports of fatal bleeding events in patients treated with dabigatran have been reported worldwide [46] [47] [48] . Many of these bleeding events appear to occur in elderly patients with chronic kidney disease, which may reflect the increased tendency of drug accumulation as 80% is eliminated by the kidney [49] .
Therefore, in contrast to the FDA, the European Medicines Agency now recommends that dabigatran not be prescribed if creatinine clearance is less than 30 ml/min [50] . The FDA is analyzing postmarketing reports of adverse events for evidence of inappropriate dosing and other clinical factors that may be associated with bleeding events. In a subgroup analysis of atrial fibrillation patients with moderate kidney disease (creatinine clearance 30-49 ml/min) randomized to rivaroxaban versus warfarin, there were comparable risk reductions with rivaroxaban, although overall event rates were higher in the moderate chronic kidney disease group. However to this day, there are no published comparative data on safety events for any of the new oral anticoagulants in patients on hemodialysis.
CONCLUSION
Given the limited evidence available, how should the clinician then manage dialysis patients with atrial fibrillation? Specifically how should (s)he weigh the risks and benefits of warfarin treatment in these patients? A recent decision analysis has used the limited information available at the time and suggested that use of warfarin was cost-effective in hemodialysis patients with atrial fibrillation, but the authors warned that considerable uncertainty was present in their study [51] . Since then, additional data have been published that cast doubt on some of the assumptions made in this model. We feel that the current evidence does not support general use of oral anticoagulation for all hemodialysis patients with atrial fibrillation. Although risk scoring algorithms such as the CHADS 2 (congestive heart failure, hypertension, age 75 years, diabetes, prior stroke or transient ischemic attack) score have been shown to predict risk of ischemic stroke in the hemodialysis population [14] , knowing a patient's risk score does not inform the relation of risks to benefits in these patients, which makes individualization of treatment decisions difficult.
Thus, we do not believe that all hemodialysis patients with atrial fibrillation should receive anticoagulation based on current risk stratification criteria (CHADS 2 ), but it may be reasonable, though of uncertain benefit, in situations of particularly high-stroke risk. In light of ambiguity of evidence and resulting clinical equipoise, conducting randomized clinical trials of anticoagulation in patients with ESRD, especially those undergoing hemodialysis, not only is ethical, but also should be a high research and funding priority. Landmark study describing the trends in the population prevalence of atrial fibrillation and associated mortality in the US hemodialysis population. 12.
